Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate

American Journal of Physiology - Endocrinology and Metabolism

Volumn 304, Issue 11, 2013, Pages

  Godoy, Alejandro S ^a,b   Chung, Ivy ^c   Montecinos, Viviana P ^a   Buttyan, Ralph ^d   Johnson, Candace S ^b   Smith, Gary J ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

Androgen receptor; Androgens; Endothelium; Prostate cancer; Vitamin D

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANGIOPOIETIN 1; BEVACIZUMAB; BICALUTAMIDE; CALCITRIOL; CYCLIN A; CYCLIN D1; DOCETAXEL; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; GOSERELIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; PRASTERONE; PREDNISONE; PROTEIN KINASE B; RETINOID X RECEPTOR; SORAFENIB; SUNITINIB; TESTOSTERONE; TRANSCRIPTION FACTOR FKHR; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VITAMIN D; VITAMIN D RECEPTOR;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN METABOLISM; BENIGN TUMOR; CANCER CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DRUG TARGETING; ENDOTHELIUM; ENDOTHELIUM CELL; GLIOBLASTOMA; HOMEOSTASIS; HORMONE ACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VITAMIN D METABOLISM; VITAMIN D RESPONSIVE ELEMENT;

ANDROGEN RECEPTOR; ANDROGENS; ENDOTHELIUM; PROSTATE CANCER; VITAMIN D;

ENDOTHELIAL CELLS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CALCITRIOL;

EID: 84878618822     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00602.2012     Document Type: Review

References (105)

1. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of androgen receptors in human bone. J Clin Endocrinol Metab 82: 3493-3497, 1997.
2. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117: 421-426, 2004.
3. Ali IU, Senger DR, Smith LE. Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials. Urology 57: 143-147, 2001.
4. Alonzi R, Padhani AR, Taylor NJ, Collins DJ, D'Arcy JA, Stirling JJ, Saunders MI, Hoskin PJ. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys 80: 721-727, 2011.
5. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143: 2508-2514, 2002.
6. Bikle DD, Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocr Rev 14: 3-19, 1993.
7. Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 101: 3668-3673, 2004.
8. Blauer M, Vaalasti A, Pauli SL, Ylikomi T, Joensuu T, Tuohimaa P. Location of androgen receptor in human skin. J Invest Dermatol 97: 264-268, 1991.
9. Cai J, Hong Y, Weng C, Tan C, Imperato-McGinley J, Zhu YS. Androgen stimulates endothelial cell proliferation via an androgen receptor/ VEGF/cyclin A-mediated mechanism. Am J Physiol Heart Circ Physiol 300: H1210-H1221, 2011.
10. Chen H, Lin AS, Li Y, Reiter CE, Ver MR, Quon MJ. Dehydroepiandrosterone stimulates phosphorylation of FoxO1 in vascular endothelial cells via phosphatidylinositol 3-kinase-and protein kinase A-dependent signaling pathways to regulate ET-1 synthesis and secretion. J Biol Chem 283: 29228-29238, 2008.
11. Choy M, Rafii S. Role of angiogenesis in the progression and treatment of prostate cancer. Cancer Invest 19: 181-191, 2001.
12. Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL, Johnson CS. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 69: 967-975, 2009.
13. Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS, Trump DL. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J Biol Chem 282: 8704-8714, 2007.
14. Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res 66: 8565-8573, 2006.
15. Cianciolo G, La Manna G, Cappuccilli ML, Lanci N, Della Bella E, Cuna V, Dormi A, Todeschini P, Donati G, Alviano F, Costa R, Bagnara GP, Stefoni S. VDR expression on circulating endothelial progenitor cells in dialysis patients is modulated by 25(OH)D serum levels and calcitriol therapy. Blood Purif 32: 161-173, 2011.
16. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev 8: 338-362, 1987.
17. Deeb KK, Luo W, Karpf AR, Omilian AR, Bshara W, Tian L, Tangrea MA, Morrison CD, Johnson CS, Trump DL. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics 6: 994-1000, 2011.
18. Dull P, Reagan RW Jr, Bahnson RR. Managing benign prostatic hyperplasia. Am Fam Physician 66: 77-84, 2002.
19. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8: 210-221, 2011.
20. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, Pelletier G. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3betahydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 140: 1481-1491, 1999.
21. Feldman D, Zhao XY, Krishnan AV. Vitamin D and prostate cancer. Endocrinology 141: 5-9, 2000.
22. Flynn G, Chung I, Yu WD, Romano M, Modzelewski RA, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology 70: 447-457, 2007.
23. Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 139: 441-442, 1998.
24. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
25. Formoso G, Chen H, Kim JA, Montagnani M, Consoli A, Quon MJ. Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase-and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol 20: 1153-1163, 2006.
26. Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139: 451-456, 1998.
27. Furuyama T, Kitayama K, Shimoda Y, Ogawa M, Sone K, Yoshida-Araki K, Hisatsune H, Nishikawa S, Nakayama K, Ikeda K, Motoyama N, Mori N. Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem 279: 34741-34749, 2004.
28. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 56: 4096-4102, 1996.
29. Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, Vethanayagam RR, Singh S, Mohler JL, Smith GJ. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab 300: E263-E275, 2011.
30. Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, Smith GJ. Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 149: 2959-2969, 2008.
31. Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother 49: 319-324, 1995.
32. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425, 2005.
33. Gruber HE, Hoelscher G, Ingram JA, Chow Y, Loeffler B, Hanley EN Jr. 1,25(OH)2-vitamin D3 inhibits proliferation and decreases production of monocyte chemoattractant protein-1, thrombopoietin, VEGF, and angiogenin by human annulus cells in vitro. Spine (Phila Pa 1976) 33: 755-765, 2008.
34. Grundmann M, Haidar M, Placzko S, Niendorf R, Darashchonak N, Hubel CA, von Versen-Höynck F Vitamin D improves the angiogenic properties of endothelial progenitor cells. Am J Physiol Cell Physiol 303: C954-C962, 2012.
35. Guise T. Examining the metastatic niche: targeting the microenvironment. Semin Oncol 37, Suppl 2: S2-S14, 2010.
36. Gustavsson H, Jennbacken K, Welen K, Damber JE. Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer. Prostate 68: 161-170, 2008.
37. Gustavsson H, Welen K, Damber JE. Transition of an androgendependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62: 364-373, 2005.
38. Haapala K, Kuukasjärvi T, Hyytinen E, Rantala I, Helin HJ, Koivisto PA. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 38: 474-478, 2007.
39. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13: 325-349, 1998.
40. He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S, Pitt B, Xie W, Li S. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res 98: 192-199, 2006.
41. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6: 395-404, 2009.
42. Hirsch D, Archer FE, Joshi-Kale M, Vetrano AM, Weinberger B. Decreased anti-inflammatory responses to vitamin D in neonatal neutrophils. Mediators Inflamm 2011: 598345, 2011.
43. Holick MF. Evolution and function of vitamin D. Recent Results Cancer Res 164: 3-28, 2003.
44. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 52: 213-235, 2002.
45. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61: 2736-2743, 2001.
46. Iljin K, Petrova TV, Veikkola T, Kumar V, Poutanen M, Alitalo K. A fluorescent Tie1 reporter allows monitoring of vascular development and endothelial cell isolation from transgenic mouse embryos. FASEB J 16: 1764-1774, 2002.
47. Iseki K, Tatsuta M, Uehara H, Iishi H, Yano H, Sakai N, Ishiguro S. Inhibition of angiogenesis as a mechanism for inhibition by 1alphahydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 81: 730-733, 1999.
48. Johnson CS, Chung I, Trump DL. Epigenetic silencing of CYP24 in the tumor microenvironment. J Steroid Biochem Mol Biol 121: 338-342, 2010.
49. Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 7: 494-509, 2010.
50. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 78: 319-333, 1998.
51. Kops GJ, Burgering BM. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med (Berl) 77: 656-665, 1999.
52. Kravchick S, Cytron S, Mamonov A, Peled R, Linov L. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. Urology 73: 1274-1278, 2009.
53. Krill D, DeFlavia P, Dhir R, Luo J, Becich MJ, Lehman E, Getzenberg RH. Expression patterns of vitamin D receptor in human prostate. J Cell Biochem 82: 566-572, 2001.
54. Laine M, Blauer M, Ylikomi T, Tuohimaa P, Aitasalo K, Happonen RP, Tenovuo J. Immunohistochemical demonstration of androgen receptors in human salivary glands. Arch Oral Biol 38: 299-302, 1993.
55. Lekas E, Johansson M, Widmark A, Bergh A, Damber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 25: 309-314, 1997.
56. Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, Demay MB. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 94: 9831-9835, 1997.
57. Liang T, Hoyer S, Yu R, Soltani K, Lorincz AL, Hiipakka RA, Liao S. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol 100: 663-666, 1993.
58. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 277: 21379-21388, 2002.
59. Lowe FC, Somers WJ. The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer. J Urol 137: 1000-1002, 1987.
60. Mahajan K, Coppola D, Rawal B, Chen YA, Lawrence HR, Engelman RW, Lawrence NJ, Mahajan NP. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J Biol Chem 287: 22112-22122, 2012.
61. Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Chang C, Messing EM, Wu JH. Localization of androgen receptor expression in human bone marrow. J Pathol 193: 361-366, 2001.
62. Masood R, Nagpal S, Zheng T, Cai J, Tulpule A, Smith DL, Gill PS. Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood 96: 3188-3194, 2000.
63. Merke J, Milde P, Lewicka S, Hügel U, Klaus G, Mangelsdorf DJ, Haussler MR, Rauterberg EW, Ritz E. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 83: 1903-1915, 1989.
64. Mizukami Y, Sasajima J, Ashida T, Kohgo Y. Abnormal tumor vasculatures and bone marrow-derived pro-angiogenic cells in cancer. Int J Hematol 95: 125-130, 2012.
65. Mohler JL. Ten years of progress in prostate cancer. J Natl Compr Canc Netw 10: 136-140, 2012.
66. Mooso B, Madhav A, Johnson S, Roy M, Moore ME, Moy C, Loredo GA, Mehta RG, Vaughan AT, Ghosh PM. Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1alpha-Hydroxyvitamin D5-a calcitriol analog. Genes Cancer 1: 927-940, 2010.
67. Mordan-McCombs S, Brown T, Wang WL, Gaupel AC, Welsh J, Tenniswood M. Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J Steroid Biochem Mol Biol 121: 368-371, 2010.
68. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 72: 648-659, 2002.
69. Murthy S, Agoulnik IU, Weigel NL. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 64: 362-372, 2005.
70. Nakae J, Biggs WH 3rd, Kitamura T, Cavenee WK, Wright CV, Arden KC, Accili D. Regulation of insulin action and pancreatic betacell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 32: 245-253, 2002.
71. Norata GD, Cattaneo P, Poletti A, Catapano AL. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits tumor necrosis factor alpha and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. Atherosclerosis 212: 100-106, 2010.
72. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147: 5542-5548, 2006.
73. Oesterling JE. Endocrine therapies for symptomatic benign prostatic hyperplasia. Urology 43: 7-16, 1994.
74. Oesterling JE, el Etreby MF, Gormley GJ, Imperato-McGinley JL, Roehrborn CG, Schröder FH, Tunn UW. Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection. Prog Clin Biol Res 386: 231-250, 1994.
75. Omdahl J, May B. The 25-hydroxyvitamin D 24-hydroxylase. In: Vitamin D (2nd ed.), edited by Feldman D, Pike JW, and Glorieux FH. Burlington, MA: Elsevier Academic, 2005, p. 85-104.
76. Peng Y, Li CX, Chen F, Wang Z, Ligr M, Melamed J, Wei J, Gerald W, Pagano M, Garabedian MJ, Lee P. Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am J Pathol 172: 225-235, 2008.
77. Prins GS, Birch L, Greene GL. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 129: 3187-3199, 1991.
78. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 29: 664-673, 2004.
79. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980-991, 1989.
80. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res 13: 2030-2037, 2007.
81. Schultheiss D, Badalyan R, Pilatz A, Gabouev AI, Schlote N, Wefer J, von Wasielewski R, Mertsching H, Sohn M, Stief CG, Jonas U. Androgen and estrogen receptors in the human corpus cavernosum penis: immunohistochemical and cell culture results. World J Urol 21: 320-324, 2003.
82. Shabisgh A, Tanji N, D'Agati V, Burchardt M, Rubin M, Goluboff ET, Heitjan D, Kiss A, Buttyan R. Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 140: 1920-1926, 1999.
83. Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, Buttyan R. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 36: 201-206, 1998.
84. Shabsigh A, Ghafar MA, de la Taille A, Burchardt M, Kaplan SA, Anastasiadis AG, Buttyan R. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 81: 437-444, 2001.
85. Shabsigh A, Lee B, Buttyan R. Unique morphological aspects of the rat ventral prostate gland revealed by vascular corrosion casting. Prostate 39: 240-245, 1999.
86. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 36: 83-87, 1995.
87. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
88. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 144: 3449-3455, 2003.
89. Sinha AA, Quast BJ, Reddy PK, Lall V, Wilson MJ, Qian J, Bostwick DG. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer. Exp Mol Pathol 77: 153-159, 2004.
90. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab 89: 5245-5255, 2004.
91. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952-1960, 1993.
92. Somjen D, Kohen F, Gayer B, Kulik T, Knoll E, Stern N. Role of putative membrane receptors in the effect of androgens on human vascular cell growth. J Endocrinol 180: 97-106, 2004.
93. Somjen D, Kohen F, Jaffe A, Amir-Zaltsman Y, Knoll E, Stern N. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension 32: 39-45, 1998.
94. Strohmeyer D, Rössing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 42: 26-33, 2000.
95. Tempany CM, Partin AW, Zerhouni EA, Zinreich SJ, Walsh PC. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate 22: 39-42, 1993.
96. Ting HJ, Bao BY, Hsu CL, Lee YF. Androgen-receptor coregulators mediate the suppressive effect of androgen signals on vitamin D receptor activity. Endocrine 26: 1-9, 2005.
97. Trump DL, Muindi J, Johnson CS, Hershberger PA. Clinical development of calcitriol and calcitriol analogs in oncology: progress and considerations for future development. In: Vitamin D (2nd ed.). Burlington, MA: Elsevier Academic, 2005, p. 1741-1749.
98. Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 106: 2136-2142, 2006.
99. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 380: 297-309, 2004.
100. Wang S, Lai K, Moy FJ, Bhat A, Hartman HB, Evans MJ. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinology 147: 4025-4033, 2006.
101. Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev 38: 89-116, 2006.
102. Woloszynska-Read A, Johnson CS, Trump DL. Vitamin D and cancer: clinical aspects. Best Pract Res Clin Endocrinol Metab 25: 605-615, 2011.
103. Yu WD, McElwain MC, Modzelewski RA, Russell DM, Smith DC, Trump DL, Johnson CS. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 90: 134-141, 1998.
104. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62: 1008-1013, 2002.
105. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139: 1197-1207, 1998.